Australia-based Schott Minifab, which develops and manufactures microfluidic devices for point-of-care and life sciences consumables, has worked with AMI to develop biotech substrates for diagnostics applications.
The deal, expected to close in early October, expands Schott Minifab’s biosensor printing capabilities as demand grows for point-of-care microarray consumables for applications such as infectious disease testing. Tempe, Arizona-based AMI will soon move to a larger facility in the Phoenix area.
“We pride ourselves on being an end-to-end partner for the global diagnostics industry,” said Greg Wolters, head of Schott Minifab, in a news release. “Our expansive offering allows us to provide an integrated single-source collection of value-intensive services and products. With the added bioscience knowledge of AMI, we become an even stronger partner, enhancing our capability in surface modification, functionalization and deposition for both glass and polymer products.”
Schott Minifab’s parent company, Schott, is headquartered in Mainz, Germany.